Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus FLO as first-line treatment for advanced gastric cancer
2010-024379-15Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib, fluorouracil, folinic acid and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Progression-free survival rate at 6 months. Started Jul 2011; status: completed.
02
Drugs
pazopanibfluorouracilfolinic acidoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-024379-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024379-15.